| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 268 | 206 | 411 | 361 | 363 | 478 | 417 | 398 | 388 | 501 | 588 | 569 | 581 | 609 | 655 | 609 | 638 | 693 | 782 | 790 | 812 | 879 |
| Expenses | 203 | 165 | 268 | 268 | 258 | 330 | 283 | 264 | 259 | 358 | 412 | 411 | 413 | 449 | 475 | 459 | 475 | 509 | 559 | 585 | 599 | 679 |
| EBITDA | 65 | 40 | 143 | 93 | 105 | 148 | 134 | 134 | 129 | 143 | 177 | 158 | 168 | 160 | 180 | 150 | 163 | 184 | 223 | 205 | 213 | 200 |
| Operating Profit % | 24 % | 18 % | 34 % | 26 % | 28 % | 30 % | 31 % | 33 % | 31 % | 28 % | 27 % | 27 % | 28 % | 26 % | 27 % | 24 % | 25 % | 26 % | 28 % | 24 % | 25 % | 22 % |
| Depreciation | 17 | 17 | 16 | 20 | 17 | 17 | 18 | 19 | 19 | 29 | 31 | 33 | 35 | 32 | 33 | 35 | 46 | 39 | 41 | 45 | 53 | 53 |
| Interest | 10 | 9 | 7 | 9 | 7 | 6 | 3 | 3 | 4 | 6 | 8 | 12 | 5 | 9 | 9 | 12 | 16 | 18 | 20 | 26 | 27 | 33 |
| Profit Before Tax | 38 | 14 | 120 | 65 | 81 | 125 | 113 | 112 | 107 | 107 | 138 | 113 | 127 | 119 | 139 | 102 | 100 | 127 | 162 | 135 | 134 | 114 |
| Tax | 10 | 5 | 29 | 17 | 22 | 33 | 29 | 28 | 24 | 28 | 31 | 31 | 29 | 32 | 37 | 26 | 29 | 32 | 42 | 42 | 28 | 29 |
| Net Profit | 28 | 9 | 90 | 48 | 59 | 92 | 84 | 84 | 83 | 79 | 106 | 82 | 99 | 87 | 101 | 77 | 72 | 95 | 121 | 93 | 106 | 85 |
| EPS in ₹ | 3.72 | 1.49 | 11.21 | 6.55 | 7.72 | 11.48 | 10.34 | 10.14 | 10.08 | 8.74 | 12.14 | 9.49 | 11.65 | 10.10 | 11.50 | 8.98 | 8.18 | 10.82 | 2.68 | 2.22 | 2.54 | 1.96 |
Krishna Institute of Medical Sciences
Krishna Institute of Medical Sciences
732.60
+6.15
(0.85%)
Market Cap
29,068.10 Cr
EPS
9.61
PE Ratio
78.92
Dividend Yield
0.00 %
Industry
Healthcare Services52 Week High
798.40
52 Week Low
474.05
PB Ratio
13.60
Debt to Equity
0.99
Sector
Hospitals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
Company News
View All News
Krishna Institute Of Medical Sciences has begun operations at a new 450-bed multi-specialty hospital in Mahadevapura, Bengaluru. The facility includes over 120 ICU beds and more than 100 OPD beds. This marks the company's first expansion into the Bengaluru area.
KIMS Targets 25-30% Revenue Growth Over Next Four Years, Plans to Boost ARPOB to Rs 55,000
Aug 23, 2025
Aug 23, 2025Krishna Institute of Medical Sciences Ltd. (KIMS) is targeting 25-30% year-on-year revenue growth over the next three to four years, according to Chairman and Managing Director Dr Bhaskar Rao. The company aims to increase its Average Revenue Per Occupied Bed (ARPOB) from the current Rs 43,000 to Rs 55,000. KIMS is opening 900 beds this year in Bangalore and Thane, which are expected to contribute to higher ARPOBs within two quarters. The company's debt stands at approximately Rs 600-700 crore with a debt-to-Ebitda ratio of less than 1:1. The blended debt-to-Ebitda ratio including subsidiaries is around 2.5, which management aims to reduce to 1.5-2 or preferably below 1.5. KIMS shares closed 0.96% lower at Rs 739 on the NSE.
KIMS Hospital Reports 26.8% Revenue Growth to INR879 Crores in Q1 FY26, EBITDA Margins Decline to 22.7%Aug 13, 2025
Krishna Institute of Medical Sciences Limited reported revenue of INR879 crores for Q1 FY26, marking 26.8% year-on-year growth and 9.6% quarter-on-quarter growth. EBITDA stood at INR200 crores with 8.5% year-on-year growth but declined 1.4% quarter-on-quarter. EBITDA margin compressed to 22.7% from 26.6% in Q1 FY25 and 25.3% in Q4 FY25. PAT decreased to INR85 crores from INR95 crores in Q1 FY25 and INR106 crores in Q4 FY25. The company launched new units including Thane facility and two Bangalore units with 800 beds capacity. New hospital operations faced combined losses of INR21 crores in Q1, with Thane contributing INR11 crores, Nashik INR7 crores, and Kannur INR3.5 crores. Management expects EBITDA losses of INR8-10 crores from Maharashtra cluster in Q2 and additional INR10-15 crores drag from Bangalore units starting September. The company operates 25 centers across 5 states with 8,000 bed capacity and projects EBITDA margins in 22-25% range for the fiscal year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,137.70 | #1 1,10,163.70 | 91.89 | 7,184.10 | #1 28.68 | 1,076 | 30.34 | 37.25 | |
7,624.00 | 1,09,901.80 | 69.85 | #1 21,994.30 | 14.76 | #1 1,505 | 39.78 | 43.97 | |
944.60 | 72,506.20 | 78.56 | 7,849.70 | 13.25 | 809 | #1 53.33 | 58.10 | |
1,328.70 | 35,469.60 | 62.18 | 3,771.40 | 21.40 | 481 | 49.58 | 41.15 | |
1,720.40 | 35,174.60 | #1 44.45 | 5,575.00 | 12.29 | 790 | -2.38 | 39.33 | |
642.55 | 32,778.90 | 91.63 | 4,286.70 | 15.12 | 337 | -98.18 | 54.22 | |
732.60 | #7 29,068.10 | #7 78.92 | #7 3,067.00 | #2 21.98 | #6 415 | #8 -10.71 | 41.87 | |
1,385.10 | 14,137.00 | 54.97 | 1,566.90 | 17.46 | 244 | 35.52 | 25.10 | |
1,541.10 | 9,958.20 | 51.73 | 1,290.20 | 17.77 | 194 | -1.57 | 67.40 | |
655.25 | 9,069.70 | 244.45 | 2,257.70 | 12.97 | 49 | -55.88 | 43.69 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
21.98 %
Net Income Growth
23.49 %
Cash Flow Change
11.63 %
ROE
6.85 %
ROCE
-11.21 %
EBITDA Margin (Avg.)
2.27 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 958 | 1,118 | 1,196 | 1,436 | 1,907 | 2,941 | 3,852 | 5,736 |
| Fixed Assets | 755 | 863 | 916 | 931 | 1,005 | 1,766 | 2,434 | 3,349 |
| Current Assets | 156 | 174 | 220 | 451 | 393 | 478 | 547 | 697 |
| Capital Work in Progress | 0 | 0 | 2 | 9 | 21 | 477 | 600 | 1,214 |
| Investments | 0 | 0 | 0 | 0 | 333 | 68 | 157 | 99 |
| Other Assets | 203 | 254 | 278 | 496 | 549 | 630 | 660 | 1,075 |
| Total Liabilities | 958 | 1,118 | 1,196 | 1,436 | 1,907 | 2,941 | 3,852 | 5,736 |
| Current Liabilities | 749 | 201 | 219 | 278 | 215 | 297 | 452 | 836 |
| Non Current Liabilities | 347 | 351 | 366 | 282 | 282 | 707 | 1,307 | 2,481 |
| Total Equity | -138 | 566 | 611 | 876 | 1,411 | 1,938 | 2,093 | 2,419 |
| Reserve & Surplus | -209 | 466 | 523 | 786 | 1,307 | 1,590 | 1,748 | 2,058 |
| Share Capital | 50 | 75 | 75 | 78 | 80 | 80 | 80 | 80 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 5 | -11 | 5 | 3 | -3 | 33 | 12 | -27 | 36 | -15 | 9 |
| Investing Activities | -71 | -41 | -100 | -64 | -110 | -125 | -354 | -412 | -416 | -753 | -1,116 |
| Operating Activities | 64 | 95 | 82 | 106 | 134 | 202 | 356 | 324 | 432 | 521 | 582 |
| Financing Activities | 12 | -66 | 24 | -39 | -27 | -44 | 10 | 61 | 20 | 217 | 543 |
Share Holding
| % Holding | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.82 % | 38.82 % | 38.82 % | 38.82 % | 38.82 % | 38.82 % | 34.11 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 8.61 % | 8.61 % | 0.00 % | 14.25 % | 0.00 % | 16.73 % | 17.84 % | 15.85 % | 15.68 % | 15.45 % | 15.54 % |
| DIIs | 13.81 % | 16.11 % | 18.35 % | 18.49 % | 20.46 % | 27.98 % | 28.32 % | 29.76 % | 33.03 % | 34.80 % | 31.63 % | 33.13 % | 32.12 % | 32.30 % | 32.05 % | 31.95 % | 31.66 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 13.14 % | 14.23 % | 13.38 % | 12.88 % | 11.81 % | 11.50 % | 11.32 % | 11.10 % | 11.22 % | 11.15 % | 10.84 % | 10.73 % | 10.61 % | 10.55 % | 10.97 % | 11.24 % | 11.58 % |
| Others | 34.21 % | 30.82 % | 29.42 % | 29.79 % | 28.88 % | 21.68 % | 12.92 % | 11.69 % | 16.91 % | 0.96 % | 18.70 % | 0.59 % | 0.61 % | 2.48 % | 2.48 % | 2.54 % | 7.11 % |
| No of Share Holders | 0 | 267 | 86,389 | 74,355 | 73,664 | 70,795 | 67,735 | 60,980 | 65,449 | 66,957 | 71,014 | 69,092 | 69,063 | 77,617 | 95,468 | 1,01,895 | 1,08,955 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 Aug 2024 |  Annual General Meeting | NA | 29 Aug 2024 | 389.93 | 502.38 |
| 28 Jun 2024 |  Split | 2:10 | 13 Sept 2024 | 420.62 | 420.62 |
| 09 Nov 2024 |  Quarterly Result Announcement | NA | 09 Nov 2024 | 520.35 | 570.15 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 606.05 | 649.15 |
| 12 May 2025 | Quarterly Result Announcement | NA | 12 May 2025 | 657.35 | 635.00 |
| 06 Aug 2025 | Quarterly Result Announcement | NA | 06 Aug 2025 | 763.85 | 741.05 |
| 29 Aug 2025 | Annual General Meeting | NA | 29 Aug 2025 | 635.00 | 737.40 |
Announcements
Closure of Trading Window1 hour ago
1 hour agoCommencement Of Operations At KIMS Hospital Mahadevapura Bengaluru10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Sep 08, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 01, 2025
Sep 01, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 26, 2025
Aug 26, 2025It Has Come To Attention That The Annexure Containing Additional Information Of The Director Seeking Re-Appointment As Required Under Regulation 36(3) Of The SEBI (LODR) Regulations 2015 And Secretarial Standard On General Meetings (SS-2) Issued By The InAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Aug 09, 2025Web-Link Of The Integrated Annual Report For The Financial Year 2024-25Aug 07, 2025
Aug 07, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 07, 2025
Aug 07, 2025Reg. 34 (1) Annual Report.Aug 07, 2025
Aug 07, 2025Notice Convening The 23Rd Annual General MeetingAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 06, 2025
Aug 06, 2025ResultsAug 06, 2025
Aug 06, 2025Board Meeting Outcome for Outcome Of Board Meeting For Q1FY26Aug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2025
Jul 30, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 25, 2025
Jul 25, 2025Board Meeting Intimation for The Approval Of The Unaudited (Standalone & Consolidated) Financial Results Of The Company For The 01St Quarter Ended June 30 2025.Jul 24, 2025
Jul 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 12, 2025
Jul 12, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 23, 2025
Jun 23, 2025Closure of Trading WindowJun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 21, 2025
Jun 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2025
Jun 09, 2025Allotment Of Equity Shares By KIMS Hospital Bengaluru Private Limited A Wholly-Owned Subsidiary Of The Company On Preferential Basis.Jun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 12, 2025
May 12, 2025Re-Appointment Of Mrs. Y. Prameela Rani As An
Independent Director For The Further Period Of 5 Years W.E.F 19.05.2025.May 12, 2025
May 12, 2025Appointment Of Secretarial Auditors And Appointment Of Cost Auditors.May 12, 2025
May 12, 2025Results-Financial Result For The Quarter And Year Ended 31.03.2025May 12, 2025
May 12, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 12, 2025
May 12, 2025Board Meeting Intimation for KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED Has Informed The Exchange About Board Meeting To Be Held On 12-May-2025 To Inter-Alia Consider And Approve The Audited Financial Results Of The Company For The Yearly Ended March 2May 02, 2025
May 02, 2025KIMS : Krishna Institute Of Medical Sciences Limited Has Informed Regarding Receipt Of Approval Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Apr 28, 2025
Apr 28, 2025Closure of Trading WindowMar 24, 2025
Mar 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 24, 2025
Mar 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Mar 19, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 18, 2025
Mar 18, 2025Technical Indicators
RSI(14)
Neutral 41.87
ATR(14)
Less Volatile 17.86
STOCH(9,6)
Neutral 23.43
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish -2.67
ADX(14)
Weak Trend 11.77
UO(9)
Bearish 43.85
ROC(12)
Downtrend And Accelerating -1.30
WillR(14)
Oversold -96.91
Mutual Fund Holdings
Invesco India Large & Mid Cap Fund Direct-Growth 
ICICI Prudential Midcap Direct Plan-Growth 
Axis Consumption Fund Direct-Growth 
Edelweiss Multi Cap Fund Direct - Growth 
UTI Quant Fund Direct - Growth 
Capitalmind Flexi Cap Fund Direct - Growth 
Samco Special Opportunities Fund Direct - Growth 
TRUSTMF Flexi Cap Fund Direct - Growth 
ITI Small Cap Fund Direct-Growth 
JM Small Cap Fund Direct - Growth 
Aditya Birla Sun Life Small Cap Fund Direct-Growth 
Union Small Cap Fund Direct-Growth 
Shriram Flexi Cap Fund Direct - Growth About Krishna Institute of Medical Sciences
Krishna Institute of Medical Sciences Limited (KIMS) is an Indian healthcare company operating 12 multispecialty hospitals under the KIMS Hospitals brand. With over 4,000 beds, KIMS provides tertiary and quaternary healthcare services across more than 40 specialties and super specialties. The company's network includes hospitals in Telangana, Andhra Pradesh, and Maharashtra. KIMS offers medical education programs through affiliations with state medical boards and universities. The company's hospitals are equipped with advanced medical technology, including robotic surgical systems and specialized imaging equipment. KIMS has received various accreditations and awards for its healthcare services and facilities. In recent developments, Sunshine Hospitals became a subsidiary of KIMS in 2022, and the company opened a new gastroenterology unit in Vizag.
Listing Date
28 Jun, 2021(4 Years,
-3 days)
Chairperson NameBhaskara Rao Bollineni
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
